U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Quinupristin Dalfopristin – Injection products
  1. Development Resources

Quinupristin Dalfopristin – Injection products

Recognized Interpretive Criteria

 

Minimum Inhibitory
Concentrations

(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Staphylococcus aureus
(methicillin susceptible)

M100 standard is recognized

Streptococcus spp. β-
Hemolytic Group

M100 standard is recognized

Streptococcus spp.
Viridans group

M100 standard is recognized

S = Susceptible; I = Intermediate; R = Resistant

Exceptions to the recognized standard of CLSI M100

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Enterococcus spp.

Streptococcus pneumonia

Back to Top